TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16941239
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control (NT)
Study: 16281522
Drug: Methanthelinium bromide
Normalized name: Methanthelinium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methanthelinium bromide 50 mg orally twice daily for 4 weeks
Study: 9289631
Drug: 20% sucralfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sucralfate suspension
Study: 9289631
Drug: 1 gram
Normalized name: guar gum 1 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram sucralfate chewable tablets
Study: 8214949
Drug: Flurbiprofen (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (prostaglandin synthetase inhibitor)
Study: 3612641
Drug: Multivitamin/multimineral with
Normalized name: Multivitamin/Multimineral with Folic acid Oral tablet, biphasic release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/multimineral with 65 mg of iron
Study: 26263033
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (2.4 ± 0.7 L/min)
Study: 23857313
Drug: Dichoptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichoptic treatment combined with visual cortex direct current stimulation
Study: 23857313
Drug: Dichoptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichoptic treatment alone
Study: 8853223
Drug: ondansetron 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.25 mg bd
Study: 25342704
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (HP) beverage (1.5 g/100 ml)
Study: 25342704
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein (LP) beverage (0.75 g/100 ml)
Study: 25342704
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) beverage (0 g/100 ml)
Study: 23576048
Drug: Casein (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (30 g, 15N-labeled)
Study: 23576048
Drug: Whey proteins
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey proteins (30 g)
Study: 29331328
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (control)
Study: 18051216
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a high-dose, standardized, 3-grass pollen extract
Study: 16087920
Drug: Levodopa (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (single oral dose)
Study: 9305335
Drug: Gabapentin 2400
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 2400 mg/d
Study: 30509271
Drug: Empagliflozin/Metformin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin/Metformin (25 mg and 2000 mg daily, respectively)
Study: 23086332
Drug: G-Bond (GB,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond (GB, GC)
Study: 21946199
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy + anti-Helicobacter pylori therapy
Study: 10868867
Drug: Active PENS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PENS treatment
Study: 8173690
Drug: Felodipine-metoprolol combination
Normalized name: felodipine / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol combination tablet (extended-release), administered once daily, dosage individually titrated until blood pressure control achieved.
Study: 8173690
Drug: Felodipine-metoprolol combination
Normalized name: felodipine / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol combination tablet (extended-release) for 24 months (Swedish/UK study).
Study: 8173690
Drug: Felodipine-metoprolol combination
Normalized name: felodipine / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol combination tablet (extended-release) with hydrochlorothiazide added if necessary (12.5 or 25 mg daily).
Study: 8173690
Drug: Felodipine-metoprolol combination
Normalized name: felodipine / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol combination tablet (extended-release).
Study: 26908839
Drug: Gonadotropin suppression
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin suppression (testosterone enanthate + GnRH antagonist acyline)
Study: 26908839
Drug: Gonadotropin suppression
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin suppression (testosterone enanthate + levonorgestrel + GnRH antagonist acyline)
Study: 26908839
Drug: Gonadotropin suppression
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin suppression (testosterone enanthate + levonorgestrel + 5α‐reductase inhibitor dutasteride)
Study: 20688040
Drug: LEISH-F1+MPL-SE vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEISH-F1+MPL-SE vaccine (5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 μg MPL-SE adjuvant)
Study: 7531487
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2 i.v. bolus weekly)
Study: 26928845
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel daily for 14 weeks
Study: 26928845
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel daily for 14 weeks
Study: 23118021
Drug: Low-dose MDMA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MDMA (25 mg, plus 12.5 mg supplemental dose)
Study: 23118021
Drug: Full-dose MDMA
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose MDMA (125 mg, plus 62.5 mg supplemental dose)
Study: 10440423
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg in fasting state
Study: 10440423
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg in fed state
Study: 10440423
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg with antacid (Maalox 2 x 400 mg tablets 1 hour before dosing)
Study: 10440423
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg without antacid
Study: 8558205
Drug: Buthionine sulfoximine
Normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buthionine sulfoximine (BSO) 1.5 to 17 g/m2 intravenously every 12 hours for six doses, followed by melphalan (L-PAM) 15 mg/m2 intravenously 1 hour after the fifth dose of BSO in the second cycle.
Study: 8558205
Drug: Buthionine sulfoximine
Normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buthionine sulfoximine (BSO) at doses >= 13 g/m2.
Study: 8558205
Drug: Buthionine sulfoximine
Normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buthionine sulfoximine (BSO) at various doses.
Study: 1805152
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin K1 intramuscularly
Study: 31246882
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Study: 29493402
Drug: Salmeterol/fluticasone Easyhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone Easyhaler (two inhalations of 50/500 μg/inhalation strength)
Study: 24923533
Drug: Comprehensive Geriatric
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Geriatric Assessment (CGA) conducted by a geriatrician before cancer treatment, participation of the same geriatrician in cancer treatment selection, a standardised geriatric therapeutic intervention designed by the same geriatrician, and geriatric follow-up for 24 months.
Study: 22934526
Drug: Shengjing prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengjing prescription
Study: 8145097
Drug: Higher potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher potency pancreatic enzyme preparations
Study: 8145097
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme preparations
Study: 8145097
Drug: Higher potency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher potency preparations
Study: 3463271
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (1 gram of elemental calcium)
Study: 30290615
Drug: Closed-loop target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop target-controlled infusion of propofol and remifentanil
Study: 30290615
Drug: Manual target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual target-controlled infusion of propofol and remifentanil
Study: 26929604
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and lung-protective ventilation strategy
Study: 22839709
Drug: ω-3 polyunsaturated
Normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 polyunsaturated fatty acids (PUFA) 1 g/day for 6 months
Study: 22839709
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard antiarrhythmic therapy without ω-3 PUFA)
Study: 20346242
Drug: Combination DMARD
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination DMARD therapy (COMBI) starting with sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone
Study: 20346242
Drug: Monotherapy (SINGLE)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (SINGLE) initially with sulfasalazine, with or without prednisolone
Study: 19067892
Drug: N-acetylcysteine (NAC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC, 30-45 mg/kg/d)
Study: 19067892
Drug: L-alanine
Normalized name: L-alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-alanine
Study: 16188807
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of 0.25 mg dexamethasone every 6 hours (group 1)
Study: 14519708
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Study: 10561249
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/d for 4 years plus Epirubicin (EPI) 50 mg/m² intravenously on days 1 and 8 every 4 weeks for six cycles
Study: 10561249
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/d for 4 years
Study: 400734
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of regular insulin
Study: 27052787
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet supplemented with nuts and pharmacological treatment
Study: 22804250
Drug: Dulaglutide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.0 mg
Study: 22804250
Drug: Dulaglutide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.1 mg
Study: 22804250
Drug: All dulaglutide
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All dulaglutide doses
Study: 20410085
Drug: DAG oil
Normalized name: Daglutril
DrugBank: Daglutril (DB05796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG oil (40 g/d)
Study: 20410085
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil (40 g/d)
Study: 14686231
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of active disease
Study: 10747210
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 1 mg after surgery with PCA delivering morphine 0.2 mg h‐1, 0.2 mg per bolus.
Study: 10747210
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 1 mg plus ketamine 5 mg after surgery with PCA delivering morphine 0.2 mg + ketamine 0.5 mg h‐1, morphine 0.2 mg + ketamine 0.5 mg per bolus.
Study: 7191313
Drug: Acemetacin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (180 mg daily in three divided doses)
Study: 7191313
Drug: Indometacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (150 mg daily in three divided doses)
Study: 20096136
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy according to the Utrecht School of Manual Therapy (MTU) for six weeks
Study: 20096136
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (standard care, mainly active exercise therapy) for six weeks
Study: 16859993
Drug: Diclofenac (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (both treatments)
Study: 7889634
Drug: 1.1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 ml/kg of 95% ethanol
Study: 25662596
Drug: VCB regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCB regimen (cisplatin 80 mg/m², oral vinorelbine 60 mg/m², and bevacizumab 15 mg/kg) followed by DGB regimen (docetaxel 75 mg/m², gemcitabine 1100 mg/m², and bevacizumab 15 mg/kg)
Study: 25662596
Drug: DCB regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCB regimen (cisplatin 80 mg/m², docetaxel 75 mg/m², and bevacizumab 15 mg/kg)
Study: 23799908
Drug: Udenafil 50
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 50 mg twice daily for 4 weeks, then 100 mg twice daily for 8 weeks
Study: 22938690
Drug: Mannose-binding lectin
Normalized name: Mannose-binding lectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannose-binding lectin deficiency (MBL levels ≤ 500 ng/ml)
Study: 17668527
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5%/clindamycin 1% gel as monotherapy
Study: 17668527
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5%/clindamycin 1% gel in combination with adapalene gel
Study: 15496273
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization
Study: 28834483
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target systolic blood pressure < 120 mm Hg)
Study: 28834483
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (target systolic blood pressure < 140 mm Hg)
Study: 18324527
Drug: Tomato extract
Normalized name: TOMATO EXTRACT CONTAINING LYCOPENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato extract (45 mg lycopene/day)
Study: 18324527
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (45 mg lycopene/day)
Study: 17163232
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg once daily (regimen A)
Study: 17163232
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg once daily (regimen B)
Study: 17163232
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg once daily plus hydrochlorothiazide 25 mg once daily (regimen C)
Study: 14604159
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of anti-epileptic drug therapy (AED)
Study: 14604159
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of anti-epileptic drug therapy (AED)
Study: 14604159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of persistent/calcified CT lesion and abnormal EEG prior to AED withdrawal
Study: 14604159
Drug: 1 vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vs. 2 years of AED therapy
Study: 10985512
Drug: Atropine 500
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine 500 mcg intramuscularly
Study: 10985512
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 1 mL intramuscularly
Study: 8874574
Drug: Pre-incisional infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after induction of general anaesthesia
Study: 8874574
Drug: Post-incisional infiltration
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after surgery
Study: 8874574
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received paracetamol 15-20 mg/kg rectally when admitted to the recovery ward
Study: 4001842
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of unconjugated chenodeoxycholic acid (CDA)
Study: 22622852
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (20 mg)
Study: 22622852
Drug: Intravenous piritramide
Normalized name: piritramide
DrugBank: Piritramide (DB12492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piritramide PCA (2 mg piritramide/ml 0.9 % saline)
Study: 22622852
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (oral oxycodone and PCA)
Study: 14674116
Drug: Iscador QuS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador QuS administered s.c. twice a week for 3 months
Study: 14674116
Drug: Intron A
Normalized name: Intron A
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intron A administered twice a week in cervical injections for 3 months
Study: 29664106
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise alone (control group with saline injection)
Study: 29664106
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline injection) vs Hyaluronate
Study: 28827103
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg per day
Study: 28827103
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg per day
Study: 11576818
Drug: Prescription from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription from a gynecologist
Study: 11576818
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitors (MAOI) or selective serotonin reuptake inhibitors (SSRI) antidepressants 3 months prior to initiation
Study: 8582196
Drug: Oestrogen-based hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestrogen-based hormone replacement therapy
Study: 2570798
Drug: Hydroxyzine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 25 mg twice daily
Study: 31576607
Drug: Almond consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond consumption (20% of daily energy for 16 weeks)
Study: 18753185
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI), n=81
Study: 18753185
Drug: Histamine-2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 receptor antagonist (H2RA), n=19
Study: 11010599
Drug: Maximal inspiratory
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal inspiratory effort (targeted peak inhalation flow 30 L/min)
Study: 11010599
Drug: Submaximal inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submaximal inspiratory effort (targeted peak inhalation flow 15 L/min)
Study: 9283989
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg once daily
Study: 8356856
Drug: Morphine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (100 micrograms/kg)
Study: 3322310
Drug: 3-palmitoyl-(+)‐catechin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-palmitoyl-(+)‐catechin at a dose of 1500 mg daily (500 mg t.d.s.) for 3 months
Study: 18678842
Drug: Rapid HIV
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid HIV testing with the OraQuick ADVANCE Rapid HIV‐1/2 Antibody Test
Study: 18678842
Drug: Reactive oral
Normalized name: MedActive Rinse Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive oral OraQuick HIV screening test
Study: 10223771
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g of 5% ibuprofen gel (topical administration)